^
    Back
    Association details:
    Biomarker:CD44 expression
    Cancer:Gastric Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Onco Targets Ther
    Title:

    ARPP-19 Mediates Herceptin Resistance via Regulation of CD44 in Gastric Cancer

    Published date:
    07/07/2020
    Excerpt:
    We observed ARPP-19 was up-regulated in Herceptin resistance gastric cancer cells NCI-N87-HR and MKN45-HR. The forced expression of ARPP-19 promoted, whereas the silencing of ARPP-19 impaired Herceptin resistance of HER2-positive gastric cancer cells both in vitro and in vivo. Moreover, ARPP-19 significantly enhanced the sphere formation capacity and CD44 expression, CD44 was also a positive factor of Herceptin resistance in HER2-positive gastric cancer cells.
    DOI:
    https://doi.org/10.2147/OTT.S253841